Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to find out if the combination of trans-arterial chemoembolization (LC or ONCOZENE BEAD) plus infusional chemotherapy is safe and more effective than just receiving the infusional chemotherapy alone.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01648023
Study type Interventional
Source University of Louisville
Contact
Status Completed
Phase Phase 2
Start date July 2012
Completion date September 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03942328 - Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer Phase 1/Phase 2
Terminated NCT02256982 - A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma N/A
Not yet recruiting NCT06058663 - Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma Phase 1
Active, not recruiting NCT04175912 - Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Phase 2
Recruiting NCT05738057 - Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma Phase 2
Terminated NCT02994251 - A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma Phase 2
Recruiting NCT05564403 - Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Phase 2
Active, not recruiting NCT03768414 - Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Phase 3
Completed NCT04301778 - Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma Phase 2
Active, not recruiting NCT04251715 - mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma Phase 2